Surgical oncologists at Chennai's Apollo Cancer Centre (ACC) have achieved a significant milestone by successfully conducting India's first robotic cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface cancer.
This minimally invasive, robotic-assisted approach signifies a paradigm shift in the treatment of Pseudomyxoma Peritonei (PMP), an aggressive form of appendix cancer.
It provides patients with a new standard of care, leading to faster recovery and an enhanced quality of life.
During the procedure, the patient was found to have residual mucinous implants in the pelvis and around the cecum. To address this, a complete mesocolic excision, peritonectomy, total omentectomy, and hyperthermic intraperitoneal chemotherapy (HIPEC) were performed, effectively eliminating any potential microscopic residual tumors within the abdomen.
Traditionally, CRS/HIPEC procedures have been conducted as open and extensive operations, involving a 10–12-inch incision and prolonged hospitalization. However, the robotic CRS approach offers significant advantages due to its minimally invasive nature, utilizing small 8-mm incisions. Furthermore, a single SCM (sternocleidomastoid) incision was utilized for tumor removal and the delivery of HIPEC, showcasing this innovative approach.
This translated into a quicker recovery and a prompt return to normal life for the patient. At the one-year follow-up, she continues to maintain perfect health status, being cancer-free.
You may like also
neet mds counselling 2024 reduced percentile special vacancy round announced
